Dr Brook Thomas Massey, MD | |
60 Mack Walters Rd, Shelbyville, KY 40065-1738 | |
(502) 633-4622 | |
(502) 633-6925 |
Full Name | Dr Brook Thomas Massey |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 27 Years |
Location | 60 Mack Walters Rd, Shelbyville, Kentucky |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679578058 | NPI | - | NPPES |
000023032T | Other | KY | HUMANA- NORTON |
64346901 | Medicaid | KY | |
3513870000 | Other | KY | PASSPORT ADVANTAGE- NORTON CMA- TYLER CTR |
515-25606 | Other | AL | SHO BCBSAL |
000000555430 | Other | KY | ANTHEM- NORTON |
000000389694 | Other | KY | ANTHEM |
50019322 | Other | KY | PASSPORT- NCMA |
051555189 | Medicaid | AL | |
6434690100 | Other | KY | MEDICAID KY- NORTON COMMUNITY MEDICAL ASSOCIATES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 25606 (Alabama) | Secondary |
207Q00000X | Family Medicine | 34690 (Kentucky) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Amedisys Home Health Services | Louisville, KY | Home health agency |
Kindred At Home | Louisville, KY | Home health agency |
Caretenders | Louisville, KY | Home health agency |
Jewish Hospital - Shelbyville | Shelbyville, KY | Hospital |
Norton Hospitals, Inc | Louisville, KY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Proactive Therapy, Inc | 0143245415 | 58 |
University Of Louisville Physicians Inc | 3476725599 | 1102 |
News Archive
Recent studies conclude that people with epilepsy have a 27-fold greater risk of sudden death than people without the disorder. However, many of these deaths could be prevented through greater identification of epilepsy as a cause of death, and in educating the public more effectively about the disease's life-threatening dangers.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
› Verified 3 days ago
Entity Name | University Of Louisville Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1366722316 PECOS PAC ID: 3476725599 Enrollment ID: O20111017000036 |
News Archive
Recent studies conclude that people with epilepsy have a 27-fold greater risk of sudden death than people without the disorder. However, many of these deaths could be prevented through greater identification of epilepsy as a cause of death, and in educating the public more effectively about the disease's life-threatening dangers.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Brook Thomas Massey, MD 100 E Liberty St Ste 800, Louisville, KY 40202-1428 Ph: (502) 633-4622 | Dr Brook Thomas Massey, MD 60 Mack Walters Rd, Shelbyville, KY 40065-1738 Ph: (502) 633-4622 |
News Archive
Recent studies conclude that people with epilepsy have a 27-fold greater risk of sudden death than people without the disorder. However, many of these deaths could be prevented through greater identification of epilepsy as a cause of death, and in educating the public more effectively about the disease's life-threatening dangers.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
› Verified 3 days ago
Dr. Ron E Creque Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Stonecrest Road, Suite 3, Shelbyville, KY 40065 Phone: 502-633-5565 Fax: 502-633-5154 | |
Dr. Ronald E Waldridge Sr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 60 Mack Walters Rd, Shelbyville, KY 40065 Phone: 502-633-4622 Fax: 502-633-6925 | |
David W Wallace, MD MBA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 Hospital Dr, Suite 1, Shelbyville, KY 40065 Phone: 502-633-3525 Fax: 502-633-8075 | |
Leticia Kathryn Allen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 60 Mack Walters Rd, Shelbyville, KY 40065 Phone: 502-633-4622 Fax: 502-633-6925 | |
Dr. William J Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 148 Midland Blvd, Shelbyville, KY 40065 Phone: 502-647-1958 Fax: 502-647-1940 | |
James R Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 Hospital Dr, Ste 1, Shelbyville, KY 40065 Phone: 502-633-3525 Fax: 502-633-8075 | |
Dr. Jena Thomas Ruxer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 727 Hospital Dr, Shelbyville, KY 40065 Phone: 502-647-4000 |